These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 11870905)

  • 1. Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
    Beauregard DA; Pedley RB; Hill SA; Brindle KM
    NMR Biomed; 2002 Apr; 15(2):99-105. PubMed ID: 11870905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Woon ST; Zwain S; Schooltink MA; Newth AL; Baguley BC; Ching LM
    Eur J Cancer; 2003 May; 39(8):1176-83. PubMed ID: 12736120
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
    McPhail LD; Griffiths JR; Robinson SP
    Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor dose response to the vascular disrupting agent, 5,6-dimethylxanthenone-4-acetic acid, using in vivo magnetic resonance spectroscopy.
    McPhail LD; Chung YL; Madhu B; Clark S; Griffiths JR; Kelland LR; Robinson SP
    Clin Cancer Res; 2005 May; 11(10):3705-13. PubMed ID: 15897567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: a comparative assessment using MRI and MRS.
    Breidahl T; Nielsen FU; Stødkilde-Jørgensen H; Maxwell RJ; Horsman MR
    Acta Oncol; 2006; 45(3):306-16. PubMed ID: 16644574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
    Siim BG; Lee AE; Shalal-Zwain S; Pruijn FB; McKeage MJ; Wilson WR
    Cancer Chemother Pharmacol; 2003 Jan; 51(1):43-52. PubMed ID: 12497205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
    Murata R; Overgaard J; Horsman MR
    Int J Radiat Biol; 2001 Feb; 77(2):195-204. PubMed ID: 11236926
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
    Ching LM; Goldsmith D; Joseph WR; Körner H; Sedgwick JD; Baguley BC
    Cancer Res; 1999 Jul; 59(14):3304-7. PubMed ID: 10416582
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
    Ching LM; Cao Z; Kieda C; Zwain S; Jameson MB; Baguley BC
    Br J Cancer; 2002 Jun; 86(12):1937-42. PubMed ID: 12085190
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Magnetic resonance imaging and spectroscopy of combretastatin A4 prodrug-induced disruption of tumour perfusion and energetic status.
    Beauregard DA; Thelwall PE; Chaplin DJ; Hill SA; Adams GE; Brindle KM
    Br J Cancer; 1998 Jun; 77(11):1761-7. PubMed ID: 9667644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The susceptibility of tumors to the antivascular drug combretastatin A4 phosphate correlates with vascular permeability.
    Beauregard DA; Hill SA; Chaplin DJ; Brindle KM
    Cancer Res; 2001 Sep; 61(18):6811-5. PubMed ID: 11559555
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of combretastatin A4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on water diffusion and blood perfusion in tumours.
    Chen G; Horsman MR; Pedersen M; Pang Q; Stødkilde-Jørgensen H
    Acta Oncol; 2008; 47(6):1071-6. PubMed ID: 18770061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Visualizing the acute effects of vascular-targeted therapy in vivo using intravital microscopy and magnetic resonance imaging: correlation with endothelial apoptosis, cytokine induction, and treatment outcome.
    Seshadri M; Spernyak JA; Maiery PG; Cheney RT; Mazurchuk R; Bellnier DA
    Neoplasia; 2007 Feb; 9(2):128-35. PubMed ID: 17356709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Acute effects of vascular modifying agents in solid tumors assessed by noninvasive laser Doppler flowmetry and near infrared spectroscopy.
    Kragh M; Quistorff B; Horsman MR; Kristjansen PE
    Neoplasia; 2002; 4(3):263-7. PubMed ID: 11988846
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
    Zhao L; Ching LM; Kestell P; Baguley BC
    Br J Cancer; 2002 Aug; 87(4):465-70. PubMed ID: 12177785
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
    Ching LM; Browne WL; Tchernegovski R; Gregory T; Baguley BC; Palmer BD
    Br J Cancer; 1998 Aug; 78(3):336-43. PubMed ID: 9703279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of serum tumour necrosis factor-alpha by thalidomide does not lead to reversal of tumour vascular collapse and anti-tumour activity of 5,6-dimethylxanthenone-4-acetic acid.
    Browne WL; Wilson WR; Baguley BC; Ching LM
    Anticancer Res; 1998; 18(6A):4409-13. PubMed ID: 9891501
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
    Cao Z; Joseph WR; Browne WL; Mountjoy KG; Palmer BD; Baguley BC; Ching LM
    Br J Cancer; 1999 May; 80(5-6):716-23. PubMed ID: 10360649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
    Zhao L; Kestell P; Ching LM; Baguley BC
    Cancer Chemother Pharmacol; 2002 Jan; 49(1):20-6. PubMed ID: 11855749
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
    Lash CJ; Li AE; Rutland M; Baguley BC; Zwi LJ; Wilson WR
    Br J Cancer; 1998 Aug; 78(4):439-45. PubMed ID: 9716024
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.